文献速递慢性肾脏病血液净化与透析肾移植

用德尔菲法确定基于证据的CKD指导优先事项

Priorities for Evidence-Based CKD Guidance Using Delphi Methods.
PubMed 文献 · Kidney Int Rep · 2026-05-06

本研究通过三轮改良德尔菲调查,在非透析CKD、腹膜透析、血液透析和移植四个模块中,识别CKD患者与健康专业人员的共同优先事项。第一轮优先主题包括CKD评估与管理、腹膜炎管理、心血管疾病管理和移植排斥;后续轮次细化为延缓CKD进展、维持残余肾功能、容量控制和药物副作用管理。患者优先日常影响,临床医生强调护理实施。

要点

  • 患者与临床医生共同确定CKD证据优先事项
  • 优先子主题包括延缓CKD进展和透析症状管理
  • 患者侧重日常影响,医生侧重护理实施

核心结论

  • 多利益相关方优先排序将肾脏护理领域提炼为可操作子主题,聚焦延缓CKD进展和改善肾脏替代治疗期间症状,为系统综述和指南更新提供靶点。

研究设计与样本

  • 三轮改良德尔菲调查,涵盖非透析CKD、腹膜透析、血液透析和移植四个模块。
  • 第一轮102人参与(27%消费者),第三轮增至613人(71%消费者)。
  • 第一轮对 broad topics 进行9点Likert评分和Best-Worst Scaling排序,第二轮细化为子主题评分,第三轮重新评分和排序。

主要发现

  • 第一轮优先主题:CKD评估与管理(8.09 ± 1.11,93%)、腹膜炎管理(7.98 ± 1.41,88%)、心血管疾病管理(7.96 ± 1.33,89%)、移植排斥(8.36 ± 1.05,96%)。
  • 第二轮和第三轮优先子主题:延缓CKD进展治疗(6.37 ± 2.53,56%)、维持残余肾功能(7.19 ± 2.10,96%)、容量控制(7.15 ± 2.12,75%)、药物副作用管理(6.65 ± 2.53,65%)。

关键数值与推荐

  • 主题进展标准包括Likert阈值、同意度(评分7-9)和BWS评分(通过多项逻辑回归估计)。
  • 数据以描述性统计总结(均值±标准差,同意百分比)。

临床怎么用

  • 优先子主题可指导针对CKD进展延缓、透析症状管理和移植药物副作用的系统综述与指南更新。
  • 患者与临床医生优先事项差异提示需在指南中平衡日常影响与护理实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Topic selection for systematic reviews and clinical practice guidelines often lacks transparent prioritization and meaningful community input. We aimed to identify shared priorities between people with lived experience of chronic kidney disease (CKD) and health-professionals to align evidence-based care with patient-clinician needs. METHODS: We conducted a 3-round modified-Delphi survey across the following 4 modules: nondialysis CKD, peritoneal dialysis (PD), hemodialysis (HD), and transplantation. Round-1 participants rated (9-point Likert) and ranked (Best-Worst Scaling [BWS]) broad topics. Priority topics were refined into subtopics and rated in round-2; round-3 re-rated and ranked priority subtopics. Topic progression criteria included Likert thresholds, agreement (scores 7-9), and BWS scores (estimated via multinomial logistic regression), with data summarized descriptively (mean ± SD, % agreement). RESULTS: Participation was 102 in round-1 (27% consumers) increasing to 613 in round-3 (71% consumers). Round-1 priority topics were as follows: Evaluation and management of CKD (8.09 ± 1.11, 93%), Infection and peritonitis management (PD; 7.98 ± 1.41, 88%), Cardiovascular disease management (HD; 7.96 ± 1.33, 89%), and Transplant rejection (8.36 ± 1.05, 96%). Across rounds 2 and 3, the prioritized subtopics were as follows: Treatment to slow CKD progression (6.37 ± 2.53, 56%), Maintenance of residual kidney function (PD; (7.19 ± 2.10, 96%), Volume control (HD; 7.15 ± 2.12, 75%), and Management of medication side-effects (transplantation; 6.65 ± 2.53, 65%). Where consumer-clinician differences emerged, consumers prioritized daily-life impacts (symptoms/side-effects, psychosocial support, infection prevention, and education), whereas clinicians emphasized care delivery (protocols, eligibility, and monitoring). CONCLUSION: This multistakeholder prioritization distilled broad kidney care domains into actionable subtopics, centered around slowing CKD progression and improving symptoms during kidney replacement therapy, providing targeted systematic reviews and guideline updates supporting shared decision-making in CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cashmore B, Howell M, Guha C, et al. Priorities for Evidence-Based CKD Guidance Using Delphi Methods. Kidney Int Rep. 2026. PMID: 42375702. doi:10.1016/j.ekir.2026.106573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。